Biliary Tract Cancer Market Report 2026

The biliary tract cancer market size has grown strongly in recent years. It will grow from $0.72 billion in 2025 to $0.77 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of biliary tract malignancies, limited effectiveness of conventional chemotherapy, advancements in molecular profiling techniques, growing awareness among healthcare professionals, expansion of oncology treatment infrastructure.

The biliary tract cancer market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing approvals of novel targeted drugs, rising investments in rare cancer research, growing adoption of personalized medicine, expansion of biomarker-based diagnostics, improving patient access to advanced oncology care. Major trends in the forecast period include increasing adoption of targeted therapy approaches, rising use of immunotherapy in treatment regimens, growing focus on early diagnosis and screening programs, expansion of precision oncology research, enhanced clinical trial activity for rare cancers.

The rising rates of obesity are anticipated to boost the biliary tract cancer market in the years ahead. Obesity represents a long-term health issue marked by an unhealthy buildup of body fat that harms overall well-being. This surge in obesity stems from elements like sedentary lifestyles, mental health influences, advancing age, and genetic or biological predispositions. Obesity sparks ongoing inflammation, insulin resistance, and heightened bile acid production, which cause DNA damage and promote tumor development. It further imbalances hormones and metabolic processes, creating conditions ripe for cancer in the biliary tract. For instance, in September 2024, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that the number of states with adult obesity rates at 35% or above increased from 22 in 2022 to 23 in 2023. Thus, the growing obesity epidemic is fueling expansion in the biliary tract cancer market.

Major companies in the biliary tract cancer market are prioritizing the development of advanced combination treatments to boost efficacy and enhance patient outcomes. Combination therapy involves using two or more drugs or treatment methods at the same time to address a single disease. For example, in November 2023, Merck & Co. Inc., a U.S.-based pharmaceutical firm, gained U.S. Food and Drug Administration (FDA) approval for KEYTRUDA (pembrolizumab) combined with gemcitabine and cisplatin to treat patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This approval stemmed from the Phase 3 KEYNOTE-966 trial, which showed a statistically significant boost in overall survival, lowering the death risk by 17% versus chemotherapy alone. The median overall survival reached 12.7 months for patients on the combination therapy, compared to 10.9 months for those on chemotherapy only, representing a major step forward in options for this difficult cancer.

In October 2023, Bristol Myers Squibb, a U.S.-based biopharmaceutical firm creating novel oncology and immunology treatments, bought Mirati Therapeutics for $4.8 billion. Through this deal, Bristol Myers Squibb sought to bolster its oncology portfolio by incorporating Mirati’s targeted therapies, such as a program targeting MTAP-deleted tumors like cholangiocarcinoma (bile-duct cancer), thus enhancing its standing in rare and difficult-to-treat cancers. Mirati Therapeutics, a U.S.-based firm, specializes in discovering, developing, and commercializing innovative cancer therapies.

Major companies operating in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., Helsinn Group.

North America was the largest region in the biliary tract cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary tract cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biliary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biliary tract cancer market by increasing costs of imported active pharmaceutical ingredients, biologics, diagnostic reagents, and advanced laboratory equipment used in targeted therapy and immunotherapy development. Research institutions and healthcare providers in North America and Europe are most affected due to dependence on globally sourced oncology drugs and diagnostics, while Asia-Pacific faces higher costs in clinical trial supplies. These tariffs are raising treatment and research expenses and slowing cross-border collaboration. However, they are also encouraging domestic drug manufacturing, localized clinical research, and regional supply chain strengthening for oncology therapeutics.

The biliary tract cancer market research report is one of a series of new reports that provides biliary tract cancer market statistics, including biliary tract cancer industry global market size, regional shares, competitors with a biliary tract cancer market share, detailed biliary tract cancer market segments, market trends and opportunities, and any further data you may need to thrive in the biliary tract cancer industry. This biliary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a rare malignancy that arises in the bile ducts, gallbladder, or ampulla of Vater. This cancer disrupts bile flow, which plays a crucial role in digestion and waste elimination. Research and treatment efforts of biliary tract cancer focus on early detection, advancing therapeutic options, and improving survival rates for affected patients.

The primary types of biliary tract cancer include intrahepatic bile duct cancer, extrahepatic bile duct cancer, and gallbladder cancer. Intrahepatic cholangiocarcinoma represents a rare form of liver bile duct cancer that may cause obstruction of bile flow. Treatment options encompass chemotherapy, targeted therapy, and immunotherapy, serving various end users such as hospitals, specialty cancer centers, ambulatory surgical centers, and others.

The biliary tract cancer market consists of revenues earned by entities by providing services such as diagnosis and screening services, supportive care, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. The biliary tract cancer market also includes sales of surgical instruments, pain management medications, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.